Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $45.5MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Stephen P. Robertson | Officer | Aug 21 '26 | Proposed Sale | $15.30 | 47,000 | $719,100 | — | Aug 21 08:54 PM |
| Gregory Keenan | Former Affiliate | Jun 05 '26 | Proposed Sale | $16.52 | 9,593 | $158,490 | — | Jun 05 04:27 PM |
| Gregory Keenan | Former Affiliate | Jun 04 '26 | Proposed Sale | $16.34 | 25,000 | $408,435 | — | Jun 04 04:12 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.